Literature DB >> 183397

[Antibody titers--curse in patients with recurring Herpes simplex virus infections under vaccination with heat-inactivated Herpes viruses].

W Remy, G Antoniadis, H Bockendahl, B Remy.   

Abstract

Follow-up studies of antibody-titres in patients suffering from recidivations of herpes labialis and progenitalis treated with herpes virus vaccine inactivated by heat. It was stated by several authors that patients suffering from recidivations of herpes labialis and progenitalis can be successfully treated with a herpes virus vaccine inactivated by heat (Lupidon G/H). Nothing is known, however, about the mechanisms diminishing recurrences. We have studied 11 patients and 3 control persons whether there were changes in specific antibody titres after repeated vaccinations. Skin reactions following intradermal injections were also tested. Serum samples studied over a period of 8 weeks until 9 months showed that the antibody titres found by complement-fixation and neutralization tests remained practically constant. Skin tests were always negative. Therefore it merits further study to find out the mode of action of this clinically successful treatment.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 183397

Source DB:  PubMed          Journal:  Z Hautkr        ISSN: 0301-0481


  4 in total

1.  Animal studies on the efficacy of an inactivated herpes simplex virus vaccine against recurrent herpes infection.

Authors:  M Scriba
Journal:  Infection       Date:  1978       Impact factor: 3.553

2.  Vaccination for herpes simplex genitalis.

Authors:  T Nasemann; S W Wassilew
Journal:  Br J Vener Dis       Date:  1979-04

3.  Animal studies on the efficacy of vaccination against recurrent herpes.

Authors:  M Scriba
Journal:  Med Microbiol Immunol       Date:  1982       Impact factor: 3.402

4.  [Therapy of recurrent herpes simplex and its surveillance by MIF determination: with levamisole, BCG, urushiol and herpes antigen vaccine (author's transl)].

Authors:  R Jarisch; I Sandor
Journal:  Arch Dermatol Res       Date:  1977-04-27       Impact factor: 3.017

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.